June 13, 2013

Genovis is moving to new premises

Regulatory

Genovis and the wholly owned subsidiary GeccoDots are joining forces and moving in September from their premises in Lund and Malmö, respectively, to new premises in Medicon Village, Lund.

“The new premises are ideal for our operations and the Medicon Village concept opens the door for inspiring meetings between academia, new technology and business. Unexpected ideas are often born in cross-border encounters between cutting edge expertise and enterprise,” says Sarah Fredriksson, CEO of Genovis.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00

Release
  • Svenska